Full text is available at the source.
Phytomedicine : international journal of phytotherapy and phytopharmacology···
Muscone may restore cell death sensitivity in drug-resistant brain tumor cells by blocking a specific growth and attachment signaling pathway
Updated
Abstract
Muscone treatment reduced the expression of the DNA repair enzyme TOP2A in TMZ-resistant glioblastoma cells.
- 97 deregulated chemotherapy-resistant genes and 3779 upregulated genes were identified in TMZ-resistant glioblastoma cells.
- Muscone inhibited migration and proliferation of U251-TR cells in a dose-dependent manner.
- Co-administration of muscone with TMZ may enhance therapeutic efficacy against resistant GBM cells.
- Muscone downregulated FAK, reducing anoikis resistance in anchorage-independent U251-TR cells.
- Cell cycle arrest was induced by muscone, with upregulation of p21 and downregulation of CDK1, CDK2, and Cyclin E1.
- Muscone treatment resulted in significant DNA damage and reduced TOP2A expression, linked to mitochondrial-dependent anoikis.
Simplified
BACKGROUND: Temozolomide (TMZ) resistance is the main obstacle faced by glioblastoma multiforme (GBM) treatment. Muscone, one of the primary active pharmacological ingredients of Shexiang (Moschus), can cross the blood-brain barrier (BBB) and is being investigated as an antineoplastic medication. However, muscone treatment for GBM has received little research, and its possible mechanisms are still unclear.
PURPOSE: This study aims to evaluate the effect and the potential molecular mechanism of muscone on TMZ-resistant GBM cells.
METHODS: The differentially expressed genes (DEGs) between TMZ-resistant GBM cells and TMZ-sensitive GBM cells were screened using GEO2R. By progressively raising the TMZ concentration, a relatively stable TMZ-resistant human GBM cell line was established. The drug-resistance traits of U251-TR cells were assessed via the CCK-8 assay and Western Blot analysis of MGMT and TOP2A expression. Cell viability, cell proliferation, cell migration ability, and drug synergism were detected by the CCK-8 assay, colony formation assay, wound healing assay, and drug interaction relationship test, respectively. Anoikis was quantified by Calcein-AM/EthD-1 staining, MTT assay, and flow cytometry. Measurements of cell cycle arrest, apoptosis, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) were performed using cell cycle staining, Annexin V-FITC/PI labeling, JC-1 assay, and ROS assay, respectively. DNA damage was measured by TUNEL assay, alkaline comet assay, and γ-H2AX foci assay. GEPIA was used to investigate the link between the anoikis marker (FAK)/drug resistance gene and critical proteins in the EGFR/Integrin β1 signaling pathway. Molecular docking was used to anticipate the probable targets of muscone. The intracellular co-localization and expression of EGFR and FAK were shown using immunofluorescence. The U251-TR cell line stably overexpressing EGFR was constructed using lentiviral transduction to assess the involvement of EGFR-related signaling in anoikis resistance. Western Blot was employed to detect the expression of migration-related proteins, cyclins, anoikis-related proteins, DNA damage/repair-related proteins, and associated pathway proteins.
RESULTS: DEGs analysis identified 97 deregulated chemotherapy-resistant genes and 3779 upregulated genes in TMZ-resistant GBM cells. Subsequent experiments verified TMZ resistance and the hyper-expression of DNA repair-related genes (TOP2A and MGMT) in continuously low-dose TMZ-induced U251-TR cells. Muscone exhibited dose-dependent inhibition of U251-TR cell migration and proliferation, and its co-administration with TMZ showed the potential for enhanced therapeutic efficacy. By downregulating FAK, muscone reduced anoikis resistance in anchorage-independent U251-TR cells. It also caused cell cycle arrest in the G2/M phase by upregulating p21 and downregulating CDK1, CDK2, and Cyclin E1. Muscone-induced anoikis was accompanied by mitochondrial membrane potential collapse, ROS production, an increase in the BAX/Bcl-2 ratio, as well as elevated levels of Cytochrome c (Cyt c), cleaved caspase-9, and cleaved caspase-3. These findings indicated that muscone might trigger mitochondrial-dependent anoikis via ROS generation. Moreover, significant DNA damage, DNA double-strand breaks (DSBs), the formation of γ-H2AX foci, and a reduction in TOP2A expression are also associated with muscone-induced anoikis. Overexpression of EGFR in U251-TR cells boosted the expression of Integrin β1, FAK, β-Catenin, and TOP2A, whereas muscone suppressed the expression levels of EGFR, Integrin β1, β-Catenin, FAK, and TOP2A. Muscone may influence the expression of the key DNA repair enzyme, TOP2A, by suppressing the EGFR/Integrin β1/FAK pathway.
CONCLUSION: We first demonstrated that muscone suppressed TOP2A expression through the EGFR/Integrin β1/FAK pathway, hence restoring anoikis sensitivity in TMZ-resistant GBM cells. These data suggest that muscone may be a promising co-therapeutic agent for enhancing GBM treatment, particularly in cases of TMZ-resistant GBM with elevated TOP2A expression.
Related papers
Jul '23
Quercetin may cause death of glioblastoma cells with MGMT by blocking two key growth and survival pathways
top 10% journal
cited by 55 papers
journal article
Mar '22
Tubeimoside-I helps overcome chemotherapy resistance in brain cancer cells by lowering a repair protein and blocking a growth signaling pathway
top 10% journal
cited by 46 papers
journal article
Aug '18
β-catenin may help cordycepin lower MGMT levels and reduce temozolomide resistance in glioma cells by increasing cell oxidative stress
top 5% journal
cited by 46 papers
research support, non-u.s. gov't
Aug '22
Activated TRPA1 may help overcome chemotherapy resistance in brain tumors by changing mitochondrial behavior
top 30% journal
cited by 19 papers
journal article
Oct '21
Blocking serine production may improve temozolomide treatment by lowering DNA repair and oxidative damage in brain cancer
top 20% journal
cited by 29 papers
journal article
Feb '24
Lowering DNA methyltransferase 3B by blocking the PI3K/Akt pathway may increase glioblastoma's sensitivity to temozolomide chemotherapy
top 10% journal
cited by 2 papers
journal article
Apr '19
miR-126-3p may make brain cancer cells more responsive to temozolomide by blocking the Wnt/β-catenin pathway through targeting SOX2
cited by 55 papers
journal article
Oct '12
ATM inhibitor KU-55933 boosts temozolomide response only in glioblastoma cells already sensitive to temozolomide
cited by 60 papers
research support, n.i.h., extramural
Feb '22
Temozolomide increases COX-2 levels in human brain cancer cells
top 20% journal
cited by 19 papers
journal article